Pharmanutra S.p.A. (BIT:PHN)

Market Cap	691.33M +76.2%
Revenue (ttm)	143.70M +17.9%
Net Income	20.74M +22.8%
EPS	2.17 +22.9%
Shares Out	9.58M
PE Ratio	33.35
Forward PE	25.36
Dividend	1.20 (1.66%)
Ex-Dividend Date	May 4, 2026

Volume	10,247
Open	70.20
Previous Close	70.90
Day's Range	70.20 - 72.60
52-Week Range	38.75 - 95.90
Beta	0.16
Analysts	Strong Buy
Price Target	95.67 (+32.51%)
Est. Earnings	Nov 10, 2026

About Pharmanutra

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for mu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 144
• Stock Exchange: Borsa Italiana
• Ticker Symbol: PHN

Financial Performance

In 2025, Pharmanutra's revenue was 132.16 million, an increase of 13.78% compared to the previous year's 116.15 million. Earnings were 20.00 million, an increase of 20.44%.

Analyst Summary

According to 3 analysts, the average rating for PHN stock is "Strong Buy." The 12-month stock price target is €95.67, which is an increase of 32.51% from the latest price.

Price Target

€95.67

(32.51% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error